ACKNOWLEDGEMENTS     VIII

ABBREVIATIONS     X

1. SUMMARY PERFORMANCE OF MALARIA RDTs:
    WHO PRODUCT TESTING: ROUNDS 1-3     1
    1.1. Introduction     1
    1.2. The WHO Product Testing Programme     1
    1.3. Results of the evaluation     2
    1.4. Summary of outcomes     3
    1.5. Use of these results     3

2. WHO MALARIA RDT PRODUCT TESTING:
    ROUND 3 EXECUTIVE SUMMARY     13
    2.1. Introduction     13
    2.2. The WHO Product Testing Programme     13
    2.3. Results of the evaluation     13
    2.4. Use of these results     14

3. BACKGROUND     15

4. OBJECTIVE     16

5. MATERIALS AND METHODS     17
    5.1. Test selection     17
    5.2. Outline of the Product Testing Protocol     17
    5.3. Evaluation panels     19
    5.4. RDT registration     20
    5.5. Specimen panel registration     20
    5.6. Test phases     20
    5.7. Performing rapid tests     20
    5.8. Interpretation of results     20

6. DATA MANAGEMENT     21

7. QUALITY ASSURANCE     22

8. ETHICAL CONSIDERATIONS     22

9. DATA ANALYSIS     23
    9.1. Measures of parasite detection: panel detection score and positivity rates     23
    9.2. False-positive results     23
        9.2.1. Incorrect species identification     23
        9.2.2. False-positives from Plasmodium-negative samples     23
    9.3. Band intensity     23
    9.4. Lot agreement     23
    9.5. Invalid tests     23
    9.6. Heat (thermal) stability     24

10. LABORATORY VERSUS FIELD-BASED
    MALARIA RDT EVALUATIONS     24
11. RESULTS 25
11.1. Summary 25
11.2. Phase 1 - *P. falciparum* culture panel 30
11.3. Phase 2 - Wild-type *P. falciparum* and *P. vivax* and *Plasmodium* spp. negative samples 31
  11.3.1. *P. falciparum* detection 31
  11.3.2. *P. vivax* detection 32
  11.3.3. Combined detection of *P. falciparum* and *P. vivax* 33
  11.3.4. *P. falciparum* and *P. vivax* positivity rate 33
  11.3.5. Band intensity 34
  11.3.6. False-positive rates 35
12. HEAT STABILITY 37
12.1. *P. falciparum* test lines 40
12.2. Pan-specific test lines 43
13. EASE OF USE DESCRIPTION 45
14. DISCUSSION OF KEY FINDINGS 49
  14.1. Panel Detection Score (PDS) and its relationship to sensitivity 49
  14.2. False-positive rate and specificity 50
  14.3. Heat (thermal) stability 50
  14.4. Ease of use description 51
  14.5. Inter-lot variability 51
  14.6. Target antigens and species 52
15. USING THESE RESULTS TO ENSURE QUALITY OF DIAGNOSIS IN THE FIELD 52
  15.1. Beyond procurement 52
  15.2. Lot testing 53
16. CONCLUSIONS 53
17. REFERENCES 54
ANNEXES 55
  Annex 1: Characteristics of rapid malaria tests in Round 3 56
  Annex 2: Malaria RDT guide to results interpretation 58
  Annex 3: Phase 1 results 70
  Annex 4: Phase 2 results 74
  Annex 5a: Selection of an appropriate RDT 104
  Annex 5b: RDT format review and ease of use assessment 105
  Annex 6: Introducing RDT-based malaria diagnosis into national programmes 106

Reference to any company or product in this report, particularly in any of the figures or tables, does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) any list of companies or products is complete and/or error free; and/or that (2) any products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion in this report does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). Any lists of RDTs are not an exhaustive list of malaria RDTs. Such lists reflect those products which have been submitted for evaluation in Round 3 of the WHO Malaria RDT Product Testing Programme. The fact that certain products are not included in any list means that they have not or not yet been submitted for evaluation in the WHO Malaria RDT Product Testing Programme and does not indicate anything in respect of such products’ performance. WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of or in connection with the procurement, distribution and use of any product whatsoever included in this report. This report may not be used by manufacturers and suppliers for commercial or promotional purposes.
FIGURES

Figure S1: Malaria RDT performance in Phase 2 of Rounds 1-3 against wild-type (clinical) samples containing *P. falciparum* at low (200) and high (2000 or 5000) parasite densities (parasites/µl) and clean-negative samples

Figure S2: Malaria RDT performance in Phase 2 of Rounds 1-3 against wild-type (clinical) samples containing *P. vivax* at low (200) and high (2000 or 5000) parasite densities (parasites/µl) and clean-negative samples

Figure 1: Mode of action of antigen-detecting malaria RDTs

Figure 2: Network of specimen collection, characterization and testing sites

Figure 3: Malaria RDT Product Testing Overview

Figure 4a: Origin of Phase 2 *P. falciparum* wild-type (clinical) samples

Figure 4b: Origin of Phase 2 *P. vivax* wild-type (clinical) samples

Figure 5: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 200 parasites/µl

Figure 6: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 2000 parasites/µl

Figure 7: Phase 1 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/µl) according to target antigen type (HRP2 or pLDH)

Figure 8: Phase 2 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/µl) according to target antigen type (HRP2 or pLDH)

Figure 9: Phase 2 *P. vivax* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/µl) according to target antigen type (aldolase, pLDH)

Figure 10: Phase 2 *P. falciparum* panel detection score and positivity rate at 200 parasites/µl

Figure 11: Phase 2 *P. vivax* panel detection score and positivity rate at 200 parasites/µl

Figure 12: Phase 2 *P. falciparum* (*P. falciparum* test line) false-positive rate against clean-negative samples

Figure 13: Phase 2 *Plasmodium* spp. (pan or *P. vivax* test line) false-positive rate against clean-negative samples

Figure 14: Phase 2 *P. falciparum* false-positive rate versus *P. falciparum* panel detection score at low (200) parasite density (parasites/µl)

Figure 15: Phase 2 *P. vivax* false-positive rate versus *P. vivax* panel detection score at low (200) parasite density (parasites/µl)

Figure 16: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a low density *P. falciparum* sample (200 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 17: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a high density *P. falciparum* sample (2000 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 18: Heat stability of *P. falciparum*-specific test line in combination tests against a low density *P. falciparum* sample (200 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 19: Heat stability of *P. falciparum* specific test line in combination tests against a high density *P. falciparum* sample (2000 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 20: Heat stability of pan-line of pan-specific tests against a low density *P. falciparum* sample (200 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 21: Heat stability of pan-line of pan-specific tests against a high density *P. falciparum* sample (2000 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 22: Heat stability of pan-line of combination tests against a low density *P. falciparum* sample (200 parasites/µl). Positivity rate at baseline, and after 60 days incubation

Figure 23: Heat stability of pan-line of combination tests against a high density *P. falciparum* sample (2000 parasites/µl). Positivity rate at baseline, and after 60 days incubation.

Figure A6.1: Example malaria RDT implementation budget
TABLES

Table S1: Malaria RDT Phase 2 performance in Rounds 1-3 against wild-type (clinical) samples containing *P. falciparum* and *P. vivax* at low (200) and high (2000 or 5000) parasite densities (parasites/µl) and clean-negative samples

Table S2: Malaria RDT Rounds 1-3 heat stability results on a cultured *P. falciparum* sample at low (200) and high (2000) parasite density (parasites/µl). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C

Table S3: Product resubmissions: WHO Malaria RDT Product Testing (Rounds 1-3)

Table 1: Manufacturers and products accepted into Round 3 of WHO Malaria RDT Product Testing Programme

Table 2: Characteristics of *Plasmodium* spp. negative specimens

Table 3: Summary Phase 1 performance of 50 malaria RDTs against 20 cultured *P. falciparum* lines at low (200) and high (2000) parasite densities (parasites/µl)

Table 4: Summary Phase 2 performance of 50 malaria RDTs against wild-type (clinical) *P. falciparum* and *P. vivax* samples at low (200) and high (2000) parasite densities (parasites/µl) and *Plasmodium* spp. negative samples

Table 5: Heat stability testing results for 50 malaria RDTs on a cultured *P. falciparum* sample at low (200) and high (2000) parasite densities (parasites/µl). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C

Table 6: Ease of use description of 50 malaria RDTs
Table A4.12a: Heat stability testing results for pan test line of combination RDTs on a *P. falciparum* sample at high parasite density (2000 parasites/µl). Positivity rate at baseline, and after 60 days incubation at 4°C, 35°C and 45°C

Table A4.13: Heat stability testing results for *P. falciparum* (or pan) test line on parasite-negative samples. Positivity rate at baseline, and after 60 days incubation at 4°C, 35°C and 45°C

Table A4.13a: Heat stability testing results for pan test line of combination RDTs on parasite-negative samples. Positivity rate at baseline, and after 60 days incubation at 4°C, 35°C and 45°C